Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Suspended 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell 1Lymphoma, Large-Cell, Anaplastic 1Immunoblastic Lymphadenopathy 1

Interventions

Cyclophosphamide 10Doxorubicin 6tanespimycin 5Vincristine 5Peripheral Blood Stem Cell Transplantation 5Ifosfamide 5Etoposide 5Cyclosporine 5fludarabine phosphate 4Prednisone 4Methotrexate 4Cytarabine 4Carboplatin 4Bortezomib 4Antilymphocyte Serum 4Vorinostat 3Rituximab 3Methylprednisolone 3Leucovorin 3Irinotecan 3Gemcitabine 3Filgrastim 3Dexamethasone 3Busulfan 3Brentuximab Vedotin 3Biopsy 3Bevacizumab 3merphos 2laromustine 2ixabepilone 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Lymphoma, Large-Cell, Anaplastic × Abatacept × Clear all
NCT07388563 2026-05-08

Azacitidine and Abatacept in Relapsed or Refractory T-Cell Lymphoma

National Institutes of Health Clinical Center (CC)

Phase 1 Suspended
20 enrolled
LymphoidOther hematologic neoplasm

Immunoblastic Lymphadenopathy, Lymphoma, T-Cell, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡